Curative Biotechnology Inc (CUBT) - Total Liabilities

Latest as of March 2025: $7.28 Million USD

Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has total liabilities worth $7.28 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Curative Biotechnology Inc operating cash flow efficiency to assess how effectively this company generates cash.

Curative Biotechnology Inc - Total Liabilities Trend (2013–2024)

This chart illustrates how Curative Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. See Curative Biotechnology Inc (CUBT) net assets for net asset value and shareholders' equity analysis.

Curative Biotechnology Inc Competitors by Total Liabilities

The table below lists competitors of Curative Biotechnology Inc ranked by their total liabilities.

Company	Country	Total Liabilities
IP Group LSE:IPO	UK	GBX123.50 Million
Kanger International Bhd KLSE:0170	Malaysia	RM36.56 Million
Biomind Labs Inc NEO:BMND	Canada	CA$1.62 Million
Viji Finance Limited NSE:VIJIFIN	India	Rs134.80 Million
Plascar Participações Industriais S.A SA:PLAS3	Brazil	R$1.31 Billion
Ignite Ltd AU:IGN	Australia	AU$4.89 Million
Babylon Pump & Power Ltd AU:BPP	Australia	AU$21.83 Million
Nisun International Enterprise Development Group Co Ltd NASDAQ:NISN	USA	$87.22 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Curative Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Curative Biotechnology Inc (CUBT) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.05	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	3.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Curative Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Curative Biotechnology Inc (2013–2024)

The table below shows the annual total liabilities of Curative Biotechnology Inc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	$7.08 Million	+23.15%
2023-12-31	$5.75 Million	-74.60%
2022-12-31	$22.62 Million	+20.48%
2021-12-31	$18.77 Million	+176.26%
2020-12-31	$6.80 Million	+1611.33%
2019-12-31	$397.10K	-45.93%
2018-12-31	$734.36K	+2.23%
2017-12-31	$718.33K	+2.28%
2016-12-31	$702.29K	+2.20%
2015-12-31	$687.16K	-28.50%
2014-12-31	$960.99K	+3.04%
2013-12-31	$932.66K	--

About Curative Biotechnology Inc

NYSE MKT:CUBT USA Biotechnology

Market Cap

$1.34 Billion

Market Cap Rank

#27675 Global

#5472 in USA

Share Price

$1.25

Change (1 day)

+4.17%

52-Week Range

$0.00 - $1.79

All Time High

$1.79